Read by QxMD icon Read

molecular thyroid cancer

Friedhelm Raue, Karin Frank-Raue
Thyroid cancer is the most common endocrine malignancy. Differentiated thyroid cancer (DTC) with the two subtypes, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC), is the most frequent subtype of thyroid cancer; more rare subtypes are medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC). The incidence of DTC has increased rapidly in recent years due to the more frequent use of imaging methods such as ultrasound of the neck and fine-needle aspiration (FNA) of thyroid nodules...
October 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Esther Diana Rossi, Maurizio Martini, Tommaso Bizzarro, Fernando Schmitt, Adhemar Longatto-Filho, Luigi Maria Larocca
This review article deals with the analysis and the detection of the morphological features associated with somatic mutations, mostly BRAFV600E mutation, on both cytological and histological samples of carcinomas. Few authors demonstrated that some architectural and specific cellular findings (i.e. polygonal eosinophilic cells defined as "plump cells" and sickle-shaped nuclei) are able to predict BRAF V600E mutation in both cytological and histological samples of papillary thyroid carcinoma (PTC) as well as in other carcinomas...
October 11, 2016: Oncotarget
Xingyun Su, Weibin Wang, Guodong Ruan, Min Liang, Jing Zheng, Ye Chen, Huiling Wu, Thomas J Fahey, Minxin Guan, Lisong Teng
Nuclear genetic alterations have been widely investigated in papillary thyroid cancer (PTC), however, the characteristics of the mitochondrial genome remain uncertain. We sequenced the entire mitochondrial genome of 66 PTCs, 16 normal thyroid tissues and 376 blood samples of healthy individuals. There were 2508 variations (543 sites) detected in PTCs, among which 33 variations were novel. Nearly half of the PTCs (31/66) had heteroplasmic variations. Among the 31 PTCs, 28 specimens harbored a total of 52 somatic mutations distributed in 44 sites...
October 10, 2016: International Journal of Molecular Sciences
Běla Bendlová, Vlasta Sýkorová, Eliška Václavíková, Josef Včelák, Rami Katra, Pavla Sýkorová, Petr Vlček, Šárka Dvořáková
Thyroid cancer is the main endocrine malignancy. Its incidence is steadily growing and what is alarming is its increase in children and adolescent population. Pediatric thyroid carcinomas differ from the adult ones in phenotype as well as in genetics. These carcinomas tend to be clinically more aggressive, with more frequent local and distant metastases. However, their long-term prognosis is better in comparison with the adult thyroid cancers. Due to the rarity of the disease, there is lack of data on genetic changes in this age group...
2016: Vnitr̆ní Lékar̆ství
Giovanni Tallini, R Michael Tuttle, Ronald A Ghossein
CONTEXT: The purpose of this review is to provide the historical context to recent developments in the classification of the follicular variant of papillary thyroid carcinoma (FVPTC), an entity that has long created significant controversy. The scope is to illustrate the evolution of the diagnostic criteria for papillary thyroid carcinoma, clarifying the role of molecular analysis, and the impact on patient management. EVIDENCE ACQUISITION: A PubMed search using the terms "follicular variant" and "papillary thyroid carcinoma" covering the years 1960-2016 was performed...
October 12, 2016: Journal of Clinical Endocrinology and Metabolism
Jan Christian Kaiser, Reinhard Meckbach, Markus Eidemüller, Martin Selmansberger, Kristian Unger, Viktor Shpak, Maria Blettner, Horst Zitzelsberger, Peter Jacob
Strong evidence for the statistical association between radiation exposure and disease has been produced for thyroid cancer by epidemiological studies after the Chernobyl accident. However limitations of the epidemiological approach in order to explore health risks especially at low doses of radiation appear obvious. Statistical fluctuations due to small case numbers dominate the uncertainty of risk estimates. Molecular radiation markers have been searched extensively to separate radiation- induced cancer cases from sporadic cases...
October 11, 2016: Carcinogenesis
Claudio Bellevicine, Roberta Sgariglia, Umberto Malapelle, Elena Vigliar, Mariantonia Nacchio, Giuseppe Ciancia, Markus Eszlinger, Ralf Paschke, Giancarlo Troncone
BACKGROUND: Fine-needle aspiration (FNA) cytology is accurate and cost-effective in the evaluation of thyroid nodules. Molecular techniques may contribute to risk stratification in indeterminate cases. Although next-generation sequencing (NGS) is a promising technique for the molecular testing of thyroid FNA specimens, thyroid-specific cancer gene panels are not commercially available. Conversely, the Ion AmpliSeq Cancer Hotspot Panel v2 (CHPv2), which includes the genes most frequently mutated in thyroid neoplasms, is commercially available and may represent an alternative to thyroid-specific panels...
September 26, 2016: Cancer
Jennifer M Johnson, Jason Chen, Siraj M Ali, Inderpreet K Dardi, Madalina Tuluc, David Cognetti, Barbara Campling, Ashwin R Sama
No abstract text is available yet for this article.
October 6, 2016: Journal of Gastrointestinal Cancer
J Capdevila, J C Galofré, E Grande, C Zafón Llopis, T Ramón Y Cajal Asensio, E Navarro González, P Jiménez-Fonseca, J Santamaría Sandi, J M Gómez Sáez, G Riesco Eizaguirre
Thyroid cancer is the single most prevalent endocrine malignancy; differentiated thyroid cancer (DTC) accounts for more than 90 % of all malignancies and its incidence has been rising steadily. For more patients, surgical treatment, radioactive iodine (RAI) ablation, and thyroid-stimulating hormone (TSH) suppressive therapy achieve an overall survival (OS) rate of 97.7 % at 5 years. Nevertheless, locoregional recurrence occurs in up to 20 % and distant metastases in approximately 10 % at 10 years. Two-thirds of these patients will never be cured with radioactive iodine therapy and will become RAI-refractory, with a 3-year OS rate of less than 50 %...
October 4, 2016: Clinical & Translational Oncology
Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, John C Morris
Anaplastic thyroid cancer (ATC) is an aggressive uncommon malignancy with limited treatment. Traditional antineoplastic chemotherapy has not been successful in the management of metastatic ATC. As a result, the focus has shifted to the development of novel therapies for this disease. The availability of economical comprehensive genomic profiling (CGP) platforms with rapid turn-around to identify molecular aberrations in tumors that are potential therapeutic targets has increasingly changed the face of cancer therapy...
October 2016: Journal of the National Comprehensive Cancer Network: JNCCN
L Casarini, G Brigante, M Simoni, D Santi
Gonadotropins (LH, FSH, and hCG) act in concert in the regulation of female reproductive system. Exploiting this influence, they are part of the assisted reproductive technique protocols. In this review we analyze the effectiveness of the different available gonadotropin formulations and the consequent adverse events. Moreover, different protocols for poor-responders and polycystic ovary syndrome affected women are explored. All these clinical different approaches have specific molecular bases, covered in this review starting from evolution and population genetics, getting to in vitro studies of gonadotropins action...
2016: Progress in Molecular Biology and Translational Science
Ranran Zhang, Heather Hardin, Wei Huang, Jidong Chen, Sofia Asioli, Alberto Righi, Francesca Maletta, Anna Sapino, Ricardo V Lloyd
Long non-coding RNAs (lncRNAs) are important for transcription and for epigenetic or posttranscriptional regulation of gene expression and may contribute to carcinogenesis. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), an lncRNA involved in the regulation of the cell cycle, cell proliferation, and cell migration, is known to be deregulated in multiple cancers. Here, we analyzed the expression of MALAT1 on 195 cases of benign and malignant thyroid neoplasms by using tissue microarrays for RNA in situ hybridization (ISH) and real-time PCR...
September 30, 2016: Endocrine Pathology
Aysenur Ozderya, Sule Temizkan, Aylin Ege Gul, Sule Ozugur, Mehmet Sargin, Kadriye Aydin
The prognostic importance of (18)F-fluorodeoxyglucose avidity in primary thyroid tumor and molecular basis responsible for its mechanism has not yet been well characterized. In this study, we aimed to evaluate the correlation between the maximum standardized uptake levels and B-type Raf kinase mutation positivity in incidentally detected papillary thyroid cancer patients during (18)F-fluorodeoxyglucose positron emission tomography examination. We retrospectively evaluated 6873 (18)F-fluorodeoxyglucose-positron emission tomography scans of consecutive subjects from a database search for tumor staging in 2014 at our hospital Nuclear Medicine Center...
October 1, 2016: Endocrine
Sujay Kakarmath, Howard T Heller, Caroline A Alexander, Edmund S Cibas, Jeffrey F Krane, Justine A Barletta, Neal I Lindeman, Mary C Frates, Carol B Benson, Atul A Gawande, Nancy L Cho, Matthew Nehs, Francis D Moore, Ellen Marqusee, Mathew I Kim, P Reed Larsen, Norra Kwong, Trevor E Angell, Erik K Alexander
CONTEXT: Mutations in the BRAF and RAS oncogenes are responsible for most well-differentiated thyroid cancer. Yet, our clinical understanding of how BRAF-positive and RAS-positive thyroid cancers differ is incomplete. OBJECTIVE: We correlated clinical, radiographic, and pathologic findings from patients with thyroid cancer harboring a BRAF or RAS mutation. DESIGN: Prospective cohort study Setting: Academic, tertiary care hospital Patients: 101 consecutive patients with well-differentiated thyroid cancer Main Outcome Measure: We compared the clinical, sonographic, and pathologic characteristics of patients with BRAF-positive cancer to those with RAS-positive cancer...
September 30, 2016: Journal of Clinical Endocrinology and Metabolism
Shumei Kato, Vivek Subbiah, Erica Marchlik, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock
PURPOSE: Aberrations in genetic sequences encoding the tyrosine kinase receptor RET lead to oncogenic signaling that is targetable with anti-RET multi-kinase inhibitors. Understanding the comprehensive genomic landscape of RET aberrations across multiple cancers may facilitate clinical trial development targeting RET. EXPERIMENTAL DESIGN: We interrogated the molecular portfolio of 4,871 patients with diverse malignancies for the presence of RET aberrations using Clinical Laboratory Improvement Amendments (CLIA) certified targeted next-generation sequencing (NGS) of 182 or 236 gene panels...
September 28, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Si Li, Hai-Yan Zhang, Zhen-Xian Du, Chao Li, Ming-Xin An, Zhi-Hong Zong, Bao-Qin Liu, Hua-Qin Wang
Beclin 1 has emerged as a haploinsufficient tumor suppression gene in a variety of human carcinomas. In order to clarify the role of Beclin 1 in thyroid cancer, Beclin 1 was knockdown in thyroid cancer cell lines. The current study demonstrated that knockdown of Beclin 1 resulted in morphological and molecular changes of thyroid cancer cells consistent with epithelial-mesenchymal transition (EMT), a morphogenetic procedure during which cells lose their epithelial characteristics and acquire mesenchymal properties concomitantly with gene expression reprogramming...
September 23, 2016: Oncotarget
Andrej Vogrin, Hana Besic, Nikola Besic, Maja Marolt Music
BACKGROUND: Preoperative ultrasound (US) evaluation of central and lateral neck compartments is recommended for all patients undergoing a thyroidectomy for malignant or suspicious for malignancy cytologic or molecular findings. Our aim was to find out how frequent was recurrence in regional lymph nodes in patients with follicular or Hürthle cell neoplasm and usefulness of preoperative neck US investigation in patients with neoplasm. PATIENTS AND METHODS: Altogether 737 patients were surgically treated because of follicular or Hürthle cell neoplasms from 1995 to 2014 at our cancer comprehensive center, among them 207 patients (163 females, 44 males; mean age 52 years) had thyroid carcinoma...
September 1, 2016: Radiology and Oncology
L Y Li, H L Yi
Thyroid carcinoma is one of the most common cancer in the head and neck and its incidence shows an increasing tendency. Due to the special anatomical location of thyroid carcinoma, patients will have a bad prognosis outcome when cancer invades larynx and trachea. Surgical treatment is still a preferred therapy for thyroid carcinoma with laryngotracheal invasion, because it has the advantages such as high survival rate, low recurrence rate, relieving of airway obstruction, improving of postoperative quality of life...
September 7, 2016: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
Garcilaso Riesco-Eizaguirre, Pilar Santisteban
Thyroid cancer is the most common endocrine malignancy giving rise to one of the most indolent solid cancers, but also one of the most lethal. In recent years, systematic studies of the cancer genome, most importantly those derived from The Cancer Genome Altas (TCGA), have catalogued aberrations in the DNA, chromatin, and RNA of the genomes of thousands of tumors relative to matched normal cellular genomes and have analyzed their epigenetic and protein consequences. Cancer genomics is therefore providing new information on cancer development and behavior, as well as new insights into genetic alterations and molecular pathways...
November 2016: European Journal of Endocrinology
Vinicius Ernani, Mukesh Kumar, Amy Y Chen, Taofeek K Owonikoko
Although rare, medullary thyroid cancer (MTC) exemplifies the value that ever-expanding knowledge of molecular pathways and mechanisms brings to managing challenging cancers. Although surgery can be curative for MTC in many patients, a substantial proportion of patients present with locoregional or distant metastatic disease. Once distant disease occurs, treatment options are limited, and conventional cancer treatments such as cytotoxic chemotherapy are of minimal benefit. Biomarkers such as calcitonin and carcinoembryonic antigen are important correlates of disease burden as well as predictors of disease progress, including recurrence and survival...
September 10, 2016: Cancer Treatment Reviews
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"